GlassScriptPhysician profile
Patrick Joseph Hensley
NPI 1912266255
$50,074.19
in general payments reported to CMS, 2019-2025
17 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2022: $145 · 2023: $238 · 2024: $4,763 · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $17K · Honoraria: $4,388 · Food and Beverage: $3,130 · Travel and Lodging: $1,679 · Education: $41.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,621.25 |
| Consulting Fee | $16,598.75 |
| Honoraria | $4,387.50 |
| Food and Beverage | $3,129.83 |
| Travel and Lodging | $1,678.61 |
| Education | $41.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $17,780.63 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $13,621.53 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Janssen Global Services, LLC | $6,345.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $6,060.96 | 2024-2025 | Erleada, Balversa |
| Urogen Pharma, INC. | $3,099.52 | 2023-2025 | Jelmyto |
| Immunitybio, INC. | $1,648.53 | 2024-2025 | |
| Boston Scientific Corporation | $827.86 | 2019-2025 | Ams 700, Spaceoar Vue System - 10ml |
| Angiodynamics, INC. | $175.09 | 2023-2025 | Nanoknife |
| Neotract INC. | $128.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.39 | 2025 | |
| Pfizer INC. | $100.30 | 2025 | |
| Merck Sharp & Dohme LLC | $67.30 | 2024 | Keytruda |
| Accord Healthcare, INC. | $43.49 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Medtronic USA, INC. | $33.22 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.